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1. Introduction 
Recent work on the conversion of arachidonic 
acid and the prostaglandin endoperoxides in platelets 
into thromboxane Bz (TXBJ led to the discovery of 
an unstable, biologically very active intermediate, 
thromboxane AZ (TXAJ [ 1,2] (fig.1). This com- 
pound was shown to constitute the major component 
of the previously recognized, elusive rabbit aorta- 
contracting substance [3] . The conversion into 
thromboxanes represents the major pathway in the 
metabolism of prostaglandin endoperoxides in plate- 
lets [4]. TXAz is very potent in inducing irreversible 
platelet aggregation and has a half-life of around 30 s 
in aqueous medium at 37°C [2] . Considerably longer 
half-lives of the compound were found at lower 
temperatures [5,6] . The half-life was also increased 
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in the presence of plasma [5,7] . Recently, a simple 
and sensitive radioimmunoassay was developed for 
the quantitative determination of TXAz, based on its 
rapid conversion into a stable mono-O-methyl deriva- 
tive of TXAz by excess amounts of methanol IS] 
(fig.1). The present paper is the first application of 
this method to the study of the properties of TXA, 
under various conditions. The half-life of TXAz was 
31-35 s between pH 7.4 and pH 9 and decreased at 
higher or lower pH. Addition of albumin increased 
the half-life, probably because of binding to this 
protein. Certain compounds, like bilirubin, acetyl- 
sahcylic acid, phenylbutazone, sulfa and warfarin 
decreased the protective effect of albumin. 
2. Experimental 
Platelet rich plasma (PRP), platelet poor plasma 
(PPP) and suspensions of washed human platelets were 
Fig.1. Formation of TXA, and TXB, from arachidonic acid, and the derivatization of TXA, into mono4-methyl TXB, by 
addition of methanol. 
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prepared from blood collected from healthy donors, 
who had not taken any drugs for at least one week, 
according to the earlier described procedures [5,8,9] . 
The platelet suspensions contained about 500 000 
platelets/pi. Studies on the generation and break- 
down of thromboxanes were carried out according to 
the procedure in refs. [5,9] . Briefly, TXAa was 
generated by incubation of arachidonic acid with a 
platelet suspension, or by incubation of ammonium 
arachidonate with PRP, at 37°C. After 30-40 s, the 
platelets were rapidly removed by filtration [S] . A 
sample of the clear, platelet-free filtrate was added 
with stirring to a 37°C solution of the different com- 
pounds to be tested for effect on the half-life of TXAz. 
Aliquots, 100 ~1, were removed with short intervals 
and subjected to addition of 2.5 ml methanol. Aliquots 
of these methanol treated samples were taken to 
dryness prior to measurement of TXBz and mono-o- 
methyl TXBa by radioimmunoassay [S] . 
Fig.2. TXB, and monoGmethy1 TXB, levels after addition 
of ammonium arachidonate to PRP (300 &ml). Samples 
were withdrawn before and after filtration. See ref. [S] for 
a comparison with the results from a similar experiment 
carried out in the absence of albumin (washed platelets; 
t% 32 s). 
Human serum albumin (HSA), transferrin and 
haptoglobin were from Kabi AB, Stockholm, Sweden. 
Essentially fatty acid free human albumin was from 
Sigma Chemical Co., St Louis, MO. Prealbumin was a 
generous gift from Dr P. A. Pettersson, The Bio- 
medical Center, Uppsala. 
the PPP concentration exceeded 40% of the physio- 
logical one, TXAa was as stable as in the PRP 
experiment above. 
3. Results 
The stability of TXAz was studied at different 
pH values. The generation of TXAa was carried out 
using washed platelets, at pH 7.4, and after filtration 
0.9 ml filtrate was added to 100 ~1 1 M buffer of the 
desired pH. The actual pH of the mixture wasmeasured 
after the experiment. TXA2 was found to be most 
stable between pH 7.4 and pH 9.0 (f% 31-35 s). At 
more alkaline pH the half-life of the compound was 
considerably shorter. Acidification proved to be even 
more deleteiious: already at pH 6.9, TXAz was so 
rapidly broken down that no accurate estimation of 
tt/, was possible. 
The stabilizing factor present in plasma was sought. 
EDTA and Ca” were without effect on the half-life 
of TXA,. PPP was lyophilized and subjected to 
chromatography on a Sephadex G-l 50 column to 
remove the low molecular weight fraction. The 
remaining high molecular weight fraction was as 
effective in stabilizing TXAz as PPP itself, and the 
stabilizing activity of PPP seemed to be associated 
with the albumin fraction. No TXAz stabilizing 
activity was seen associated with the proteins eluted 
before albumin. 
To test whether albumin was identical with the 
TXAz stabilizing factor in plasma, HSA was obtained, 
and also HSA essentially free from fatty acids. At 
pH 7.4, these protein preparations were almost as 
efficient as PPP in prolonging the half-life of TXA, 
(t% 2.83-2.92 min, in the presence of physiological 
concentration of HSA (45 mg/ml) (fig.3)). No differ- 
ence was seen between the two different albumin 
preparations. 
Figure 2 shows the results obtained in PRP. The According to the manufacturer, the HSA prepara- 
half-life was found to be about 3 min, as compared to tion contained small amounts of transferrin, hapto- 
around 30 s in washed platelet suspensions. The globin and prealbumin. These proteins were obtained 
greatly increased stability of TXA2 found in PRP was and investigated in similar experiments. No stabilizing 
also seen when the compound was generated by activity was observed for any of these compounds 
washed platelets and after filtration added to PPP. when tested in physiological concentrations. The HSA 
Different amounts of PPP were also tried and when was also purified by polyacrylamide gel electropho- 
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Fig.3. Half-life of TXA, in the presence of either buffer, 
pH 7.4, or human serum albumin. Percentages indicate % 
physiological concentrations (for HSA 45 mg/ml). “/ of 
TXA, given in parentheses for each experiment. 
resis [lo] . After this step, no traces of the contaminat- 
ing proteins could be detected. This pure albumin had 
a TXAz stabilizing capacity identical to that of the 
HSA before purification. 
In order to explore the possible molecular inter- 
actions between other organic compounds, known to 
be subject to albumin binding, and TXAz in this 
respect, the following compounds were checked: 
testosterone, progesterone, estrone, fl-estradiol, bili- 
rubin, vitamin Kr , warfarin, barbituric acid, acetyl- 
salicylic acid, phenylbutazone (Sigma Chemical Co.) 
and sulfadimidine (AB Ferrosan, Malmo, Sweden). 
All these compounds were preincubated overnight 
in a lo-fold excess on a molar basis with HSA (20 mg 
HSA/ml water) at pH 7.4. When these preparations 
were tested for effect on the TXAz half-life, it was 
found that several of these substances did not alter 
the stability of TXAz. Five of the compounds, how- 
ever, markedly reduced the half-life of TXA, in the 
presence of albumin, viz. acetylsalicylic acid, phenyl- 
butazone, bilirubin, warfarin (fs of TXA?, about 
1 min in all these experiments), and sulfadimidine 
(tl/, about 1.25 min). Control experiments were 
carried out with all these compounds in the absence 
of albumin; none of them showed any influence on 
TXAz stability (fn 30-35 s in all experiments). 
4. Discussion 
The persistence of TXAz in plasma has been noted 
earlier [5,7] . In the experiments by Smith et al. [7] , 
this phenomenon could to some extent be explained 
by a continuous production of the compound in PFW. 
In the present investigation, however, this possibility 
has been ruled out, because the platelets were removed 
from the incubation before the determination of the 
fs of TXAz was started, and because the same slow 
decline in the TXAz concentration was seen when 
PPP was added to a platelet-free filtrate containing 
the compound. Thus, the persistence of TXAz in 
plasma seems to be entirely caused by an increased 
stability of the compound under these conditions. 
It was stated in ref. [7] that plasma could be 
replaced by serum, but not by albumin or any of the 
Cohn fractions I-VI. In contrast, we found in this 
investigation that the TXAz -stabilizing activity of 
plasma could be attributed to albumin. This was 
shown both by Sephadex chromatography of lyoph- 
ilized PPP, by comparison of the properties of 
PPP with those of a commercial, 98% pure HSA prep- 
aration as well as a further purified HSA where no 
contaminating proteins could be detected, and finally 
by investigating the properties of several other plasma 
proteins in this respect. The reason for the discrepan- 
cies between our results and those of Smith et al. is 
not clear. However, we found that the pH greatly 
influenced the stability of TXAz. If the pH of the 
protein solutions was not adjusted to 7.5-8 in the 
experiments described in [7] , this may well be the 
reason why these authors did not find any prolonga- 
tion of the ty2 of TXAz by albumin. 
The increased stability of TXAz in the presence of 
albumin is most likely caused by binding of TXAz to 
this protein. It is well known that albumin can bind 
fatty acids tightly and in large amounts, in contrast to 
almost all other proteins (review [ 1 l] ). Albumin 
binding of prostaglandins has earlier been demonstrated 
by several investigators [ 12,131 ; the phenomenon is 
more pronounced for less polar prostaglandins [13,14]. 
Thus it is likely that a compound such as TXA2 is 
bound to a considerable degree by albumin. 
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Hormones and drugs are generally inactive when 
bound to albumin. However, this binding is reversible 
and should rather be regarded as a storage phenomenon. 
Thus, the biological effects of active substances are 
prolonged as they are protected from metabolism and 
excretion in the bound state (cf. [15,16]). In the case 
of TXA*, also the non-enzymatic, extremely rapid 
degradation in aqueous medium is slowed down by 
albumin, and no doubt this is of a considerable 
importance in vivo, e.g., for the propagation of the 
platelet aggregation during hemostasis. For the same 
reason, it is likely that compounds that influence the 
albumin binding of TXAz also interfere with the 
biological activity of this substance. Several compounds 
were found to inhibit the binding of TXAz to albumin 
- whether by competition alone or by other mecha- 
nisms as well is not known at present - viz., acetyl- 
salicylic acid, phenylbutazone, bilirubin, sulfadimidine 
and warfarin. Acetylsalicylic acid has earlier been 
found to inhibit the binding of prostaglandins to 
albumin [16,17] . Further studies on the influence of 
these compounds on the albumin binding and bio- 
logical activity of TXAz are in progress in our 
laboratory. 
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